Literature DB >> 18067045

Acute effect of furosemide on glomerular filtration rate in diastolic dysfunction.

Hariprasad Trivedi1, Thomas Dresser, Kul Aggarwal.   

Abstract

We sought to evaluate the acute effect of furosemide on glomerular filtration rate (GFR) in subjects with diastolic dysfunction. An equal number of subjects with documented diastolic dysfunction (DD) and healthy volunteers (controls) were enrolled and underwent a baseline GFR measurement via plasma clearance of technetium-99m-diethylenetriaminepentaacetic acid. Within three to seven days of the baseline, study subjects were scheduled for a second GFR study, which was performed immediately after administration of furosemide (20 mg orally and 20 mg intravenously). There were eight healthy volunteers (8 males with a mean age 42 +/- 7.8 years; 6 white, 2 Asian) and eight subjects with diastolic dysfunction (7 males, 1 female, with a mean age 64.5 +/- 9.3 years; 7 whites, 1 African-American). There was a significant post-furosemide decline in GFR in the healthy volunteers, baseline vs. post-furosemide 131.6 +/- 19.8 vs. 117 +/- 18.2 mL/min, respectively (p = 0.03), and the patients with DD, baseline vs. post-furosemide 117.5 +/- 22.3 vs. 92 +/- 21.7 mL/min, respectively (p = 0.0002). A strong trend was detected, though not statistically significant, of greater GFR decline in subjects with DD compared to the healthy volunteers, 25.5 +/- 9.9 vs. 14.6 +/- 15.6 mL/min, respectively (p = 0.12). To conclude, acute administration of furosemide might potentially cause a greater decline in GFR in subjects with diastolic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18067045     DOI: 10.1080/08860220701641777

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  5 in total

1.  Hypercalcemia in Children Using the Ketogenic Diet: A Multicenter Study.

Authors:  Colin P Hawkes; Sani M Roy; Bassem Dekelbab; Britney Frazier; Monica Grover; Jaime Haidet; James Listman; Sarianne Madsen; Marian Roan; Celia Rodd; Aviva Sopher; Peter Tebben; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

2.  MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension.

Authors:  Nina A Dzhoyashvili; Seethalakshmi R Iyer; Horng H Chen; John C Burnett
Journal:  Hypertension       Date:  2022-01-20       Impact factor: 10.190

3.  Can ACE-I Be a Silent Killer While Normal Renal Functions Falsely Secure Us?

Authors:  Ahmed Abdelaal Ahmed Mahmoud; Mark Campbell; Margarita Blajeva
Journal:  Case Rep Anesthesiol       Date:  2018-07-09

Review 4.  A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics.

Authors:  Giovanna Capolongo; Giovambattista Capasso; Davide Viggiano
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

5.  Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort study.

Authors:  Jesse K Fitzpatrick; Jingrong Yang; Andrew P Ambrosy; Claudia Cabrera; Bergur V Stefansson; Peter J Greasley; Jignesh Patel; Thida C Tan; Alan S Go
Journal:  BMJ Open       Date:  2022-01-31       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.